BRL Medicine's new generation of universal CAR-T therapy has been approved by domestic IND

MORE

BRL Medicine World's first non viral PD1 fixed-point integration CAR-T product obtained IND approval from CDE

MORE

BRL Medicine's β-Thalassemia Gene Therapy " BRL-101 " obtained IND approval from CDE

MORE

Lead the world! BRL Medicine's new generation of Quikin CAR-T research results published in Nature

MORE

BRL Medicine published in Nature Medicine that BRL-101 gene therapy for children with thalassemia has been free of transfusion dependence for more than 2 years

MORE

About BRL Medicine

At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 5 Investigator-Initiated clinical Trials (IIT) in 8 leading hospitals in China, with many pipeline projects have entered into IND application stage. 

Learn More

Gene Therapy

The world's first CRISPR gene editing
treatment of β0/β0 type thalassemia is successful

LEARN MORE

Cell Therapy

World's first clinical trial of non-viral PD1
specific targeted CART therapy achieves great breakthroughs

LEARN MORE

Product Pipeline

Subscribe:Submit
Back to top